Q-omics provides the consensus-scored ZFP30 profile across patient tissues and cancer cell-line models. ZFP30 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZFP30 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZFP30 RNA expression shows 21,108 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCS, THCA, and KIRP as cancer lineages where ZFP30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFP30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFP30 survival associations across molecular data types. ZFP30 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFP30 RNA expression–survival associations across cancer types. High ZFP30 expression shows unfavorable associations in LGG and MESO, but favorable associations in UCS, KIRC, HNSC and LUAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for ZFP30 RNA expression.
This table summarizes ZFP30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ZFP30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFP30 shows lower tumor expression in THCA and higher tumor expression in LUAD, BRCA, LIHC, CHOL and COAD. The THCA box plot shows higher ZFP30 RNA expression in normal versus tumor tissue (log2 FC = −0.469, t-test p < 0.001).
This table shows molecular features associated with ZFP30 in patient tissues and cancer cell lines. In patient samples, ZFP30 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFP30 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
